Primary or acquired resistance to anthracyclines of human cancers is partly associated with the overexpression of a membrane glycoprotein (P 170) that effluxes drugs out of cancer cells (Goldstein et al., 1989; Dalton et al., 1989) . Anthracycline resistance may be altered in vitro by a variety of agents such as verapamil (Tsuruo et al., 1982) , quinidine (Tsuruo et al., 1984) , amiodarone (Chauffert et al., 1986) or cyclosporine (Slater et al., 1986) . However, use of resistance modifiers in clinical practice is still a problem due to the toxicity of these agents that precludes the achievement of effective concentrations in patient serum (Gottesman & Pastan, 1989; Genne et al., 1990) .
In this paper we report that quinine, the widely used antimalaria drug, enhanced in vitro the cytotoxicity of epidoxorubicin in resistant colon cancer cells. Moreover, serum of quinine treated patients was demonstrated to increase the cellular accumulation of the anthracycline in resistant cells.
Materials and methods

Patients
The first patient (no. 1) was treated for a chloroquineresistant malaria; the other patients (nos2-6) were treated after informed consent with a combination of quinine and doxorubicin for anthracycline resistant tumours. Quinine was given either per os or intravenously at a daily dose ordinarily used for malaria treatment (24-30mgkg-' day-'). When given per os, the daily dose of quinine was supplied in three regular intakes. Intravenous treatment was given as continuous infusion. Patient serum was collected at steady state 48 h at least after starting quinine administration. Peak and trough plasma concentrations of quinine were determined in two patients 2 and 8 h respectively after an oral intake. Serum of one of the authors was used as control. After blood collection, serum was centrifugated and stored at -80C until assay.
Cancer cells
The DHD/K12 cancer cell line was established in our laboratory from a chemically induced colon cancer in syngeneic BDIX rats (Martin et al., 1975) . Inherent resistance of DHD/ K12 cells to anthracyclines is partly related to a drug efflux mechanism (Chauffert et al., 1984) which is efficiently inhibited by amiodarone or verapamil (Chauffert et al., 1986 (Melun, France) . Quinine formiate was used for intravenous treatment and was obtained from Vaillant-Defresne laboratories (Quinoforme, Paris, France). Quinine hydrochloride, quinidine hydrochloride and hydroquinidine hydrochloride used for in vitro experiments were obtained from Sigma (La Verpilliere, France). Verapamil hydrochloride was purchased from Biosedra laboratories (Malakoff, France).
Cytofluorescence study The intracellular accumulation of epiDXR in DHD/K12 cells was studied by UV illumination which induced a yelloworange fluorescence at the intracellular sites of anthracycline localisation. We previously reported that low accumulation of anthracyclines in nucleus of primary resistant DHD/K12 cells was related to a drug efflux mechanism (Chauffert et al., 1984) . In the presence of sufficient concentration of a drug efflux inhibitor in incubation medium, anthracycline accumulation increased in cancer cells and then a bright fluorescence was observed in nuclei. For microscopic examination, DHD/ K12 cells were cultivated for 24 h on glass coverslips then exposed for I h to epiDXR (5 jg ml-') diluted in patient or control serum. After rinsing with cold phosphate buffered saline (PBS), cells were examined under an UV fluorescence microscope (Leitz, Weitzlar, FR Germany).
EpiDXR uptake in cancer cells DHD/K12 cells in suspension were incubated for 1 h at 37°C with epiDXR (5 or g ml-') diluted in patient or control serum. After rinsing twice with cold PBS and centrifugation, cells pellets were mixed with daunorubicin diluted in borate buffer, pH!9.4. Anthracyclines were extracted by a chloro-form-methanol mixture (4:1, V/V). The values were obtained for 0.5fjgml-' verapamil, 1 igml-' quinidine and 2 jig ml-' quinine. Cell death was almost complete in the presence of 2 jg ml-' verapamil, 4 jig ml-' quinidine or 6tigml-' quinine (Figure 1 ).
Only a weak and inhomogenous fluorescence was seen in cell nuclei after a 1 h incubation of DHD/K12 cells in control serum supplemented with epiDXR (5 jig ml-'). In contrast, we observed an intense and homogenous nuclear fluorescence when cells were treated with epiDXR 5 j.g ml-' diluted in all the sera of quinine treated patients (Figure 2) .
Fluorescence microscopy allowed the demonstration of the rapid reversibility of the inhibition of anthracycline efflux by quinine. When DHD/K12 cells were incubated for 1 h in EpiDXR content in DHD/K12 cells was from 1.6 to 5.4-fold greater after a 1 h incubation in serum of quinine treated patients comparatively to control serum (Table I) . Quinine concentrations in patient serum ranged from 4.4 to 10.1 jig ml-' (Table II) serum was demonstrated by the weak difference between peak and trough concentrations in two patients treated with oral quinine.
Discussion
Although quinine appeared to be slightly less effective than quinidine or verapamil for the circumvention in vitro of the anthracycline resistance of rat colon cancer cells, its lower cardiotoxicity could be a considerable advantage for its use as multidrug resistance modifier in clinical oncology. Serum Control  170  210  1  430  870  2  280  390  3  580  1060  4  930  1250  5  800  1320  6  260  480 aMean of three determinations (maximal standard deviation = 9%). of quinine treated patients was demonstrated to increase the epiDXR accumulation in DHD/K12 anthracycline resistant cells; such an enhancing effect was obtained for quinine concentrations ranging from 4.4 to 1O. I g mlh' in patient serum. In this work, the daily dose of quinine was 25 or 30 mg kg-' day-' as usually recommended for the treatment of malaria (Hall, 1976) . Higher quinine concentrations (10-15 fig ml-') could be reached with a daily dose of 35 mg kg-' as for patients with cerebral malaria (White et al., 1982) . Risk of severe poisoning, mainly transient or permanent visual deficit, occurs only when serum levels exceeded 15 tg ml-' (Boland, 1985) . Comparatively serum concentrations of quinidine that are recommended for treatment of cardiac dysrytmias ranged from 3 to 5 tLg ml-' with risk of severe blockade of auriculoventricular conduction above 8 tLg ml-' (Holford et al., 1981) . In the study of Benson et al. (1985) , which evaluated the tolerance of verapamil given by continuous infusion (0.12 tg kg-' h-') in association with vinblastine, the maximal tolerated concentration was 0.29 jig ml-' in serum. Binding of resistance modifiers to serum proteins must also be considered before extrapolating the results of in vitro studies to clinical practice. However, no dramatic difference is registered in the binding of the present resistance modifiers to serum proteins: 90% for verapamil (Schomerus et al., 1976) , 75-95% for quinidine (Ochs et al., 1980) and quinine (Silamut et al., 1985) . Stability of quinine concentration in patient serum related to its long half-life (10 h) appears also as a propitious property for its use as a circumventing agent of the anthracycline resistance in future clinical studies.
